Overview
Fresenius Medical Care North America provides renal care through a network of dialysis facilities and outpatient cardiac and vascular labs that deliver coordinated treatment for chronically ill patients. It also offers specialty pharmacy and laboratory services and manufactures and distributes dialysis equipment, disposables, and renal medicines. The company stands out by being the world’s largest fully integrated renal care provider with an extensive network that covers care delivery, drug and lab services, and product supply. Its goal is to ensure access to comprehensive, high-quality care for people with kidney and other chronic conditions across North America.
Work here?Claim your company
Simplify's take
What believers are saying
- Third-quarter 2026 revenue stayed broadly stable, with operating income up 21% excluding TDAPA.
- 5008X treatments surpassed 1.3 million by October 2026, supporting machine replacement and consumables demand.
- FME25+ delivered €67 million in Q2 2026 savings, funding margin expansion and buybacks.
What critics are saying
- U.S. antitrust and billing probes continue in 2026, including FTC, DOJ, and Colorado litigation.
- FMCNA exited about 100 U.S. clinics in 2026, proving weaker local density can persist.
- DefenCath and binder mix created a roughly €50 million 2026 headwind, pressuring margins.
What makes Fresenius Medical Care unique
- Fresenius Medical Care controls dialysis manufacturing, clinics, and home therapy, unlike pure-play providers.
- The 5008X CAREsystem reached 348 U.S. clinics by October 2026, showing integrated pull-through.
- NxStage VersiHD and multiFiltratePRO broaden the portfolio from home dialysis to critical care.
Help us improve and share your feedback! Did you find this helpful?